Information Provided By:
Fly News Breaks for April 9, 2018
CLVS
Apr 9, 2018 | 09:01 EDT
SunTrust analyst Peter Lawson raised his price target on Clovis to $90 after the company's Rubraca was approved for second line maintenance therapy in ovarian cancer. Lawson adds that while the approval was "mostly expected", his new price target reflects an increase in the probability of success and deeper conviction for further indicators, while also pointing to a generally broader use of PARP inhibitors. The analyst keeps his Buy rating on Clovis.
News For CLVS From the Last 2 Days
There are no results for your query CLVS